CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
实体瘤 CAR-T 细胞疗法：致命吸引需要黏附
英文原题：CAR T cell therapy for solid tumors: Fatal attraction requires adhesion.
查看英文原题
CAR T cell therapy for solid tumors: Fatal attraction requires adhesion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
与血液系统恶性肿瘤相比，嵌合抗原受体（CAR）T 细胞疗法在临床研究中对实体瘤的疗效有限。Larson 等人在近期发表于《Nature》的一篇论文中报告，CAR-T 细胞对实体瘤的活性依赖 IFN 信号介导的细胞黏附；这一发现为未来提高其临床活性带来了可能。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors in clinical studies in contrast to hematological malignancies. In a paper recently published in Nature, Larson et al. report that CAR T cell activity against solid tumors depends on cell adhesion mediated by IFN signaling, opening the prospect of improving their clinical activity in the future.
论文信息
- 作者
- Bell M、Gottschalk S
- 第一作者单位
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: matthew.bell@stjude.org.United States
- 通讯作者单位
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: stephen.gottschalk@stjude.org.United States
- 文献类型
- 非美国政府资助研究 · 美国 NIH 资助研究 · 评论
- 期刊
- Med (New York, N.Y.)2022 Jun 10
- 原文标识
- PubMed 35690053 · DOI 10.1016/j.medj.2022.05.009